Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.

Wallerstedt A, Strom P, Gronberg H, Nordstrom T, Eklund M.

J Natl Cancer Inst. 2018 Nov 1;110(11):1216-1221. doi: 10.1093/jnci/djy036.

PMID:
29548030
2.

Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.

Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM.

BJU Int. 2012 Sep;110(5):651-7. doi: 10.1111/j.1464-410X.2011.10875.x. Epub 2012 Jan 30.

3.

Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study.

Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P.

BMJ. 2013 Jun 18;346:f3406. doi: 10.1136/bmj.f3406.

4.

Use of 5α-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study.

Scailteux LM, Rioux-Leclercq N, Vincendeau S, Balusson F, Nowak E, Oger E; Network of Pathologists in Brittany.

BJU Int. 2018 Jul 19. doi: 10.1111/bju.14495. [Epub ahead of print]

PMID:
30025199
5.

Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer.

Finelli A, Trottier G, Lawrentschuk N, Sowerby R, Zlotta AR, Radomski L, Timilshina N, Evans A, van der Kwast TH, Toi A, Jewett MA, Trachtenberg J, Fleshner NE.

Eur Urol. 2011 Apr;59(4):509-14. doi: 10.1016/j.eururo.2010.12.018. Epub 2010 Dec 28.

PMID:
21211899
6.

High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.

Murtola TJ, Kujala PM, Tammela TL.

Prostate. 2013 Jun;73(9):923-31. doi: 10.1002/pros.22638. Epub 2013 Jan 17.

PMID:
23334943
7.

Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors.

Taussky D, Piotte J, Zorn KC, Zanaty M, Krishnan V, Lambert C, Bahary JP, Beauchemin MC, Barkati M, Ménard C, Delouya G.

Strahlenther Onkol. 2018 Jan;194(1):17-22. doi: 10.1007/s00066-017-1176-z. Epub 2017 Jul 10.

PMID:
28695317
8.

5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.

Murtola TJ, Karppa EK, Taari K, Talala K, Tammela TL, Auvinen A.

Int J Cancer. 2016 Jun 15;138(12):2820-8. doi: 10.1002/ijc.30017. Epub 2016 Feb 11.

9.

The risk of prostate cancer for men on aspirin, statin or antidiabetic medications.

Nordström T, Clements M, Karlsson R, Adolfsson J, Grönberg H.

Eur J Cancer. 2015 Apr;51(6):725-33. doi: 10.1016/j.ejca.2015.02.003. Epub 2015 Feb 23.

PMID:
25727881
10.

5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.

Azoulay L, Eberg M, Benayoun S, Pollak M.

JAMA Oncol. 2015 Jun;1(3):314-20. doi: 10.1001/jamaoncol.2015.0387.

PMID:
26181177
11.

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.

Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, Mucci LA, Olumi AF.

JAMA Intern Med. 2014 Aug;174(8):1301-7. doi: 10.1001/jamainternmed.2014.1600.

12.

Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Carter HB, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P; American Society of Clinical Oncology/American Urological Association.

J Urol. 2009 Apr;181(4):1642-57. doi: 10.1016/j.juro.2009.01.071. Epub 2009 Feb 26. Review.

PMID:
19249063
13.

PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.

Patel AA, Chen MH, Renshaw AA, D'Amico AV.

JAMA. 2007 Oct 3;298(13):1533-8.

PMID:
17911498
14.

Association of 5α-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy.

Hong SK, Oh JJ, Lee S, Lee HM, Byun SS, Choe G, Lee SE.

Prostate. 2012 Aug 1;72(11):1187-92. doi: 10.1002/pros.22468. Epub 2011 Dec 7.

PMID:
22161951
15.

Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.

Freedland SJ, Hamilton RJ, Gerber L, Banez LL, Moreira DM, Andriole GL, Rittmaster RS.

Prostate Cancer Prostatic Dis. 2013 Sep;16(3):254-9. doi: 10.1038/pcan.2013.10. Epub 2013 Apr 9.

PMID:
23567655
17.

Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.

Fowke JH, Howard L, Andriole GL, Freedland SJ.

Eur Urol. 2014 Dec;66(6):1133-8. doi: 10.1016/j.eururo.2014.01.037. Epub 2014 Feb 9.

18.

Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.

Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.

Lancet Oncol. 2015 Dec;16(16):1667-76. doi: 10.1016/S1470-2045(15)00361-7. Epub 2015 Nov 10.

PMID:
26563502
19.

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, McLeod DG.

JAMA. 1995 Oct 25;274(16):1277-81.

PMID:
7563532
20.

A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies.

Nordström T, Bratt O, Örtegren J, Aly M, Adolfsson J, Grönberg H.

Scand J Urol. 2016;50(2):104-9. doi: 10.3109/21681805.2015.1113200. Epub 2015 Dec 1.

PMID:
26625178

Supplemental Content

Support Center